Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.64
6.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shandong Weigao Group Medical Polymer Co Ltd
Shandong Weigao Group Medical Polymer Co Ltd
Revenue
Shandong Weigao Group Medical Polymer Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Revenue
¥13B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Revenue
¥951.2m
|
CAGR 3-Years
52%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Revenue
¥5.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Revenue
¥4.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Revenue
¥8.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Revenue
¥3.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Shandong Weigao Group Medical Polymer Co Ltd
Glance View
Nestled in the bustling industrial heart of China, Shandong Weigao Group Medical Polymer Co Ltd stands as a testament to the transformative potential within the field of medical devices. Since its inception in 1988, Weigao has diligently carved out a niche within the healthcare sector, specializing in the production and distribution of medical consumables, orthopedic materials, and blood purification apparatus. The company's journey is intertwined with China's healthcare evolution, as it became a critical player in supplying hospitals and medical institutions with essential, reliable tools. By leveraging advancements in polymer science, Weigao consistently pushes the boundaries in creating high-quality, cost-effective products—a maneuver that not only reduces healthcare costs but also ensures widespread accessibility to essential medical supplies. Driven by an intricate understanding of the medical landscape, Weigao's operational model hinges on its robust vertical integration strategy. The company effectively controls every stage of its production process, from raw material procurement to product manufacturing and distribution. This control not only ensures stringent quality checks but also allows for improved economies of scale, thereby boosting its profitability margins. Revenue streams largely stem from its extensive product lineup, which includes syringes, blood bags, infusion sets, and orthopedic devices, catering to domestic demand while also penetrating international markets. The constant stream of innovations, coupled with an expanding global footprint, underscores Weigao's commitment to growth, firmly positioning it as a stalwart in the medical apparatus industry.
See Also
What is Shandong Weigao Group Medical Polymer Co Ltd's Revenue?
Revenue
13B
CNY
Based on the financial report for Jun 30, 2024, Shandong Weigao Group Medical Polymer Co Ltd's Revenue amounts to 13B CNY.
What is Shandong Weigao Group Medical Polymer Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
6%
Over the last year, the Revenue growth was -4%. The average annual Revenue growth rates for Shandong Weigao Group Medical Polymer Co Ltd have been 1% over the past three years , 6% over the past five years .
You don't have any saved screeners yet